Merck & Co doubles up on Ablynx research deal


Cut-down antibody drug developer Ablynx has agreed a second R&D partnership with US Pharma firm Merck & Co. Ablynx will receive €20 million (£17 million) up front, plus up to €10.7 million in research funding over three years. On top of that, milestone payments for any products that emerge from the collaboration could net the Belgian biotech up to €1.7 billion plus royalties.

This collaboration will focus on nanobodies (antibody fragments) directed against cancer, and builds on Merck’s previous collaboration with Ablynx for nanobodies that target voltage-gated ion channels. Ablynx also recently joined forces with Abbvie to develop nanobodies for treating rheumatoid arthritis and systemic lupus erythematosus.


Related Content

Merck & Co $460m ion channel deal

2 October 2012 Business

news image

Deal with Ablynx relates to antibody fragments

Business roundup

27 April 2011 Business

news image

Industry news, May 2011

Most Read

Chemical linguistics

24 June 2015 Comments

news image

Chemistry is not language, explains Michael Gordin. But the metaphor is useful nonetheless

A coat of many colours

22 June 2015 The Crucible

news image

Just how did lab couture settle on that little white number, asks Philip Ball

Most Commented

New and expectant mothers: assessing the risk

24 June 2015 Webinars

news image

Get current, practical and relevant guidance on how to assess the risks and implement control measures for new and expectant ...

A coat of many colours

22 June 2015 The Crucible

news image

Just how did lab couture settle on that little white number, asks Philip Ball